Analyst consensus rating
Sutro Biopharma, Inc. Analyst Consensus Rating
STRO analyst consensus rating, coverage count and price target evidence.
Direct answer
Sutro Biopharma, Inc.'s consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $47.77.
Forecast evidence checked August 12, 2026.
Get free Sutro Biopharma, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $19.28
- Average price target
- $47.77
- High price target
- $61.00
- Low price target
- $10.00
- Target upside
- +147.8%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 12, 2026
- Valid through
- August 19, 2026